GO:0032714 negative regulation of interleukin-5 production: Immune Regulation Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032714 describes any biological process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-5 (IL-5) production.
• IL-5 is a key cytokine for eosinophil maturation, activation, and survival, and its production is tightly controlled at the transcriptional and signaling level [1, 4].
• Negative regulation of IL-5 production is mediated by transcription factors such as STAT3, octamer-binding proteins, and signaling pathways including PI3K and cAMP-dependent pathways [2, 4, 6].
• Dysregulation of IL-5 production is linked to allergic diseases, eosinophilic disorders, and certain lymphomas [2, 8].
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable precise dissection of genes controlling IL-5 production [4, 6].
• Understanding this process supports development of therapies targeting eosinophilic inflammation and IL-5-driven pathologies [1, 8].
Description
Interleukin-5 (IL-5) is a cytokine primarily produced by T helper 2 (Th2) cells, mast cells, and eosinophils, and it plays a central role in eosinophil differentiation, activation, and survival. Because excessive IL-5 production drives eosinophilic inflammation in asthma, allergy, and hypereosinophilic syndromes, the mechanisms that negatively regulate IL-5 production are of major clinical and research interest [1, 8]. GO:0032714, negative regulation of interleukin-5 production, captures any process that stops, prevents, or reduces the frequency, rate, or extent of IL-5 production. This term is essential for annotating gene functions and pathways that dampen IL-5 synthesis, thereby maintaining immune homeostasis [2, 4]. Research into GO:0032714 has revealed that IL-5 production is controlled at multiple levels, including transcriptional regulation of the IL5 gene promoter, post-transcriptional modulation, and signaling cascades such as the phosphoinositide 3-kinase (PI3K) and cAMP-dependent pathways [4, 6]. For example, constitutively activated STAT3 in cutaneous T-cell lymphoma lines mediates spontaneous IL-5 production, indicating that negative regulation is bypassed in certain malignancies. Conversely, factors that enhance cAMP signaling or inhibit PI3K can suppress IL-5 production in human T cells. These findings highlight the importance of identifying the molecular players that enforce negative regulation. The study of GO:0032714 is also relevant to understanding how cytokines like IL-2 and other microenvironmental cues modulate IL-5 production [6, 7]. In vivo administration of high-dose IL-2 in cancer patients induces production of IL-5 and other cytokines, suggesting that negative regulatory mechanisms may be overwhelmed under strong immune stimulation. Thus, dissecting the negative regulation of IL-5 production is critical for developing strategies to control eosinophilic inflammation and related disorders [1, 8].
negative regulation of interleukin-5 production At A Glance
| GO ID | GO:0032714 |
|---|---|
| GO term | negative regulation of interleukin-5 production |
| Ontology | biological_process |
| Synonym | down regulation of interleukin-5 production; down-regulation of interleukin-5 production; downregulation of interleukin-5 production; inhibition of interleukin-5 production; negative regulation of IL-5 production; negative regulation of interleukin-5 biosynthetic process; negative regulation of interleukin-5 secretion |
| Major function | Reduces the frequency, rate, or extent of interleukin-5 production, thereby limiting eosinophil activation and allergic inflammation [1, 8]. |
| Related cytokine | Interleukin-5 (IL-5), a Th2 cytokine. |
| Key signaling pathways | PI3K, cAMP-dependent pathway, STAT3 [2, 6]. |
| Associated diseases | Allergic asthma, eosinophilic disorders, cutaneous T-cell lymphoma [2, 8]. |
| Research methods | CRISPR knockout, point mutation, knock-in, overexpression, RNA-seq, proteomics [4, 6]. |
What Is GO:0032714?
GO:0032714, negative regulation of interleukin-5 production, refers to any biological process that decreases the frequency, rate, or extent of interleukin-5 (IL-5) biosynthesis or secretion. This includes transcriptional repression of the IL5 gene, inhibition of signaling pathways that promote IL-5 expression, and any other mechanism that reduces the amount of IL-5 produced by a cell [1, 4].
Why Is negative regulation of interleukin-5 production Important in Cell Biology?
Negative regulation of interleukin-5 production is critical for preventing excessive eosinophilic inflammation and allergic responses. IL-5 is a key driver of eosinophil maturation, recruitment, and survival, and its overproduction is associated with asthma, atopic dermatitis, and hypereosinophilic syndromes [1, 8]. Understanding the mechanisms that suppress IL-5 production can reveal therapeutic targets for these conditions. Moreover, in cancers such as cutaneous T-cell lymphoma, constitutive activation of STAT3 leads to spontaneous IL-5 production, highlighting how loss of negative regulation can contribute to disease. Thus, GO:0032714 provides a framework for studying the molecular brakes on IL-5 synthesis and their roles in health and disease.
• Controls eosinophil homeostasis and prevents eosinophilic inflammation.
• Limits allergic airway responses and asthma exacerbations.
• Prevents spontaneous IL-5 production in malignancies such as cutaneous T-cell lymphoma.
• Modulates B cell maturation and IgA secretion through IL-5 regulation.
• Integrates signals from PI3K and cAMP pathways to fine-tune IL-5 levels.
• Affects cytokine networks during immunotherapy, e.g., high-dose IL-2 administration.
• Provides targets for anti-allergic and anti-eosinophilic therapeutics.
• Helps understand immune dysregulation in Syntenin-1 deficiency.
• Guides CRISPR-based functional genomics of cytokine regulation [4, 6].
• Supports development of biomarkers for eosinophilic disorders [1, 2].
What Happens During negative regulation of interleukin-5 production?
Transcriptional repression of the IL5 gene
In simple terms: The cell reduces the reading of the IL5 gene, leading to less IL-5 protein.
Negative regulation of IL-5 production often begins with transcriptional repression of the IL5 gene. The human IL5 promoter contains octamer binding sites that are involved in promoter activity, and their modulation can suppress transcription. Transcription factors such as STAT3 can act as activators, but negative regulators may compete or interfere with these sites. In cutaneous T-cell lymphoma lines, constitutively activated STAT3 mediates spontaneous IL-5 production, suggesting that negative regulation is impaired. Thus, transcriptional control is a key node for reducing IL-5 synthesis.
Inhibition of signaling pathways that promote IL-5 production
In simple terms: Blocking the signals that tell the cell to make IL-5.
Signaling pathways such as PI3K and cAMP-dependent pathways modulate IL-5 production in human T cells. Sensitivity of IL-5 production to the cAMP-dependent pathway is reduced by exogenous IL-2 in a PI3K-dependent way. This indicates that negative regulation can be achieved by inhibiting PI3K or enhancing cAMP signaling. Additionally, PI3K regulates IL-5-induced beta2-integrin adhesion of human eosinophils, showing that PI3K is a central node in IL-5 biology. Therefore, targeting these pathways can suppress IL-5 production.
Post-transcriptional and secretory control
In simple terms: Even if some IL-5 mRNA is made, the cell can stop it from becoming secreted protein.
Negative regulation of interleukin-5 production also includes post-transcriptional mechanisms that reduce IL-5 secretion. The GO term synonym 'negative regulation of interleukin-5 secretion' highlights this level of control. Although specific microRNAs or RNA-binding proteins are not detailed in the provided citations, the general principle is that mRNA stability, translation efficiency, and secretory trafficking can be targeted to lower extracellular IL-5 levels [1, 4]. Such mechanisms are important for rapid dampening of allergic responses.
Integration with immune microenvironment signals
In simple terms: Other immune signals can tell the cell to stop making IL-5.
The immune microenvironment influences negative regulation of IL-5 production. For instance, in vivo administration of high-dose IL-2 in cancer patients induces production of IL-5 and other cytokines, indicating that strong immune stimulation can override negative regulatory mechanisms. Conversely, anti-allergic compounds such as DeinoWall from Deinococcus radiodurans may suppress allergic responses, potentially by modulating cytokine production. Thus, external signals can either promote or inhibit IL-5 production, and negative regulation integrates these cues.
Key Genes Involved in GO:0032714 negative regulation of interleukin-5 production
The following genes and proteins are involved in the negative regulation of interleukin-5 production, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IL5 | Encodes interleukin-5 cytokine; its production is the target of negative regulation. | Core gene for studying negative regulation; promoter analysis and CRISPR knockout. |
| STAT3 | Transcription factor that can activate IL5 transcription; constitutive activation leads to spontaneous IL-5 production. | Target for negative regulation; STAT3 inhibitors may suppress IL-5. |
| PIK3CA | Catalytic subunit of PI3K; PI3K pathway modulates IL-5 production and eosinophil adhesion [1, 6]. | PI3K inhibitors can enhance negative regulation of IL-5. |
| PIK3CD | PI3K delta isoform; involved in IL-5 signaling and production. | Isoform-specific targeting for negative regulation. |
| OCT1 | Octamer-binding protein that binds IL5 promoter and influences promoter activity. | Modulating octamer sites can reduce IL5 transcription. |
| OCT2 | Octamer-binding protein involved in IL5 promoter regulation. | Potential target for transcriptional repression. |
| IL2 | Exogenous IL-2 reduces sensitivity of IL-5 production to cAMP pathway in PI3K-dependent way. | Cytokine context that modulates negative regulation. |
| SDCBP | Syntenin-1; deficiency increases intestinal immunoglobulins, possibly via cytokine modulation. | Link between IL-5 regulation and B cell responses. |
| CD19 | B cell marker; IL-5 induces maturation of surface IgA-positive B cells. | IL-5 regulation impacts B cell function. |
| IGHA1 | IgA heavy chain; IL-5 promotes IgA secretion. | Readout for IL-5 activity and negative regulation. |
| CSF2 | GM-CSF; co-produced with IL-5 in vivo during IL-2 therapy. | Cytokine network context. |
| IL6 | Produced alongside IL-5 during IL-2 administration. | Inflammatory cytokine cross-talk. |
| MCSF | Macrophage colony-stimulating factor; co-induced with IL-5. | Myeloid cytokine regulation. |
| ITGB2 | Beta2-integrin; IL-5-induced adhesion regulated by PI3K. | Eosinophil function downstream of IL-5. |
| FOXP3 | Regulatory T cell marker; may suppress IL-5 production indirectly. | Treg-mediated negative regulation. |
| GATA3 | Th2 transcription factor; promotes IL-5 production; its inhibition enhances negative regulation. | Target for suppressing Th2 cytokines. |
| RORC | Th17 transcription factor; may antagonize Th2 responses. | Cross-regulation of T cell subsets. |
| TBX21 | T-bet; Th1 transcription factor that can suppress Th2 cytokines including IL-5. | Th1/Th2 balance in negative regulation. |
How Is negative regulation of interleukin-5 production Regulated?
Negative regulation of interleukin-5 production is controlled by multiple signaling pathways and transcription factors. The PI3K pathway is a key modulator: inhibition of PI3K can reduce IL-5 production, while exogenous IL-2 reduces the sensitivity of IL-5 production to the cAMP-dependent pathway in a PI3K-dependent manner. The cAMP pathway itself can suppress IL-5 production when activated. STAT3 is a positive regulator of IL5 transcription, and its constitutive activation in lymphoma cells leads to spontaneous IL-5 production, indicating that negative regulation is bypassed. Octamer-binding proteins regulate the IL5 promoter, and their modulation can affect transcription. Additionally, in vivo IL-2 administration induces IL-5 production, suggesting that strong immune activation can overcome negative regulatory mechanisms. Thus, the process is regulated by a balance of activating and inhibitory signals.
negative regulation of interleukin-5 production and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| STAT3 | Cutaneous T-cell lymphoma with spontaneous IL-5 production | STAT3 knockout or point mutation in lymphoma cell lines |
| IL5 | Allergic asthma and eosinophilic inflammation | IL5 promoter knock-in reporter for negative regulation studies |
| PIK3CA | Eosinophil adhesion and IL-5 signaling | PIK3CA knockout in eosinophils or T cells |
| SDCBP | Increased intestinal immunoglobulins | Syntenin-1 knockout mice |
| IL2 | Cytokine release syndrome during immunotherapy | IL2 overexpression or knockout in T cells |
Allergic asthma and eosinophilic inflammation
IL-5 is a major driver of eosinophilic inflammation in asthma. Negative regulation of IL-5 production is critical to prevent excessive eosinophil activation and airway hyperresponsiveness. Compounds with anti-allergic function, such as DeinoWall from Deinococcus radiodurans, may suppress allergic responses by modulating cytokine production, including IL-5. Therefore, enhancing negative regulation of IL-5 could be a therapeutic strategy for asthma.
Cutaneous T-cell lymphoma
In cutaneous T-cell lymphoma lines, constitutively activated STAT3 mediates spontaneous IL-5 production, indicating a loss of negative regulation. This can contribute to eosinophilia and itch in lymphoma patients. Targeting STAT3 or restoring negative regulatory mechanisms may reduce IL-5-driven symptoms.
B cell dysregulation and IgA nephropathy
IL-5 induces maturation of surface IgA-positive B cells into IgA-secreting cells. Negative regulation of IL-5 production may therefore influence IgA levels. Syntenin-1-deficient mice show increased intestinal immunoglobulins, suggesting a link between IL-5 regulation and B cell responses. Dysregulated IL-5 production could contribute to IgA-mediated diseases.
Cytokine release syndrome and immunotherapy
High-dose IL-2 administration in cancer patients induces production of IL-5 and other cytokines, which can lead to systemic inflammation. Negative regulation of IL-5 production may be overwhelmed during immunotherapy, contributing to adverse effects. Understanding these mechanisms could help manage cytokine release syndrome.
From negative regulation of interleukin-5 production-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate IL-5 production? | CRISPR knockout of gene X in Jurkat or primary T cells, followed by IL-5 ELISA. |
| Does a point mutation in STAT3 affect IL-5 production? | CRISPR point mutation knock-in of STAT3 mutations in lymphoma cell lines. |
| Can a regulatory element control IL5 transcription? | Knock-in of reporter gene under IL5 promoter with mutated octamer sites. |
| Does overexpression of gene Y suppress IL-5? | CRISPR overexpression (CRISPRa) of gene Y in T cells, measure IL-5. |
| What is the role of PI3K in IL-5 production? | PI3K knockout or pharmacological inhibition in human T cells. |
| How does Syntenin-1 affect IL-5-related IgA production? | Syntenin-1 knockout mice, measure intestinal IgA and IL-5. |
How to Study the negative regulation of interleukin-5 production Process
| Method | What It Measures | Typical Application |
|---|---|---|
| ELISA | Secreted IL-5 protein levels | Quantify negative regulation in cell culture supernatants. |
| RNA-seq | IL5 mRNA and global transcriptome | Identify transcriptional changes [2, 4]. |
| CRISPR knockout screen | Genes affecting IL-5 production | Discover negative regulators. |
| Flow cytometry | Intracellular IL-5 in single cells | Analyze T cell subsets. |
| Western blot | STAT3, PI3K pathway proteins | Validate signaling changes [2, 6]. |
| Proteomics | Global protein expression | Unbiased pathway discovery. |
| Reporter assays | IL5 promoter activity | Test octamer site mutations. |
| Mouse models | In vivo IL-5 and IgA levels | Study Syntenin-1 deficiency. |
CRISPR knockout screening
Genome-wide CRISPR knockout screens can identify genes whose loss increases or decreases IL-5 production. Using IL-5 reporter cell lines or ELISA-based readouts, researchers can pinpoint negative regulators of IL-5. This approach is powerful for discovering novel components of GO:0032714.
RNA-seq and transcriptomics
RNA sequencing of T cells or eosinophils under conditions that suppress IL-5 production can reveal transcriptional changes in IL5 and related genes [2, 4]. Comparing wild-type and knockout cells helps identify pathways that negatively regulate IL-5.
Proteomics and phosphoproteomics
Mass spectrometry-based proteomics can measure IL-5 protein levels and signaling changes in PI3K or STAT3 pathways [1, 6]. Phosphoproteomics can identify post-translational modifications that mediate negative regulation.
Flow cytometry and imaging
Intracellular cytokine staining and flow cytometry allow single-cell analysis of IL-5 production in T cell subsets. Imaging can visualize IL-5 trafficking and secretion in real time.
How CRISPR Can Be Used to Study GO:0032714 negative regulation of interleukin-5 production
Knockout
CRISPR knockout of candidate negative regulators (e.g., PI3K subunits, transcription factors) can test whether their loss increases IL-5 production. For example, knocking out PIK3CA in T cells may enhance IL-5 production if PI3K negatively regulates it. Knockout of STAT3 in lymphoma cells may reduce spontaneous IL-5 production.
Point Mutation
Point mutations can mimic disease-associated variants. For instance, introducing activating STAT3 mutations in T cells can test their effect on IL-5 production. Point mutation of octamer binding sites in the IL5 promoter can assess their role in negative regulation.
Knock-in
Knock-in of reporter genes (e.g., GFP) under the IL5 promoter allows real-time monitoring of IL-5 production. Knock-in of tagged IL-5 enables tracking of secretion. This is useful for high-throughput screens.
Overexpression
CRISPR activation (CRISPRa) can overexpress candidate negative regulators to test if they suppress IL-5 production. Overexpression of cAMP pathway components may reduce IL-5. This approach validates gain-of-function effects.
How EDITGENE Supports negative regulation of interleukin-5 production Research
Researchers studying negative regulation of interleukin-5 production-related genes often need to determine whether a candidate gene is causally involved in suppressing IL-5 synthesis or whether it is merely correlated. EDITGENE provides comprehensive CRISPR-based services to establish causality through precise genome editing, from knockout to knock-in and overexpression models.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of interleukin-5 production research.
Frequently Asked Questions About negative regulation of interleukin-5 production
What is GO:0032714?
GO:0032714 is the Gene Ontology term for negative regulation of interleukin-5 production, describing any process that stops, prevents, or reduces the frequency, rate, or extent of IL-5 production.
What genes are involved in negative regulation of interleukin-5 production?
Key genes include IL5, STAT3, PIK3CA, PIK3CD, OCT1, OCT2, IL2, and SDCBP, among others [2, 4, 5, 6].
How is IL-5 production negatively regulated?
It is regulated at transcriptional, post-transcriptional, and signaling levels, involving PI3K, cAMP pathways, and transcription factors like STAT3 [2, 4, 6].
What diseases are associated with dysregulated IL-5 production?
Allergic asthma, eosinophilic inflammation, cutaneous T-cell lymphoma, and cytokine release syndrome are associated with altered IL-5 regulation [1, 2, 7, 8].
Which signaling pathways suppress IL-5 production?
The cAMP-dependent pathway and inhibition of PI3K can suppress IL-5 production in human T cells.
How can CRISPR be used to study negative regulation of IL-5?
CRISPR knockout, point mutation, knock-in, and overexpression can test the causal role of specific genes in IL-5 regulation [2, 4, 6].
What is the role of STAT3 in IL-5 production?
Constitutively activated STAT3 mediates spontaneous IL-5 production in cutaneous T-cell lymphoma lines, indicating it is a positive regulator.
Does IL-2 affect IL-5 production?
Exogenous IL-2 reduces the sensitivity of IL-5 production to the cAMP-dependent pathway in a PI3K-dependent way.
What model systems are used to study IL-5 negative regulation?
Human T cell lines, primary T cells, eosinophils, and mouse models such as Syntenin-1-deficient mice are commonly used [5, 6].
Why is negative regulation of IL-5 important for allergy?
It prevents excessive eosinophil activation and allergic inflammation, making it a therapeutic target for asthma and related disorders [1, 8].
Conclusion
GO:0032714, negative regulation of interleukin-5 production, is a critical biological process that maintains immune homeostasis by limiting IL-5 synthesis. Dysregulation of this process contributes to allergic diseases, eosinophilic disorders, and certain lymphomas [1, 2, 8]. Understanding the genes and pathways involved, such as STAT3, PI3K, and cAMP signaling, provides opportunities for therapeutic intervention [2, 6]. CRISPR-based models are invaluable for dissecting these mechanisms and validating causal roles of candidate genes [4, 6]. EDITGENE offers comprehensive services to support such research, from knockout to overexpression and library screening.
References
- 1. Sano M et al.. 2005. Regulation of interleukin-5-induced beta2-integrin adhesion of human eosinophils by phosphoinositide 3-kinase.. Am J Respir Cell Mol Biol 33(1):65-70 PMID: 15802551
- 2. Nielsen M et al.. 2002. Spontaneous interleukin-5 production in cutaneous T-cell lymphoma lines is mediated by constitutively activated Stat3.. Blood 99(3):973-7 PMID: 11807001
- 3. Matsumoto R et al.. 1989. Interleukin-5 induces maturation but not class switching of surface IgA-positive B cells into IgA-secreting cells.. Immunology 66(1):32-8 PMID: 15493259
- 4. Gruart-Gouilleux V et al.. 1995. Characterization of the human interleukin-5 gene promoter: involvement of octamer binding sites in the gene promoter activity.. Eur J Immunol 25(5):1431-5 PMID: 7774647
- 5. Tamura K et al.. 2015. Increased production of intestinal immunoglobulins in Syntenin-1-deficient mice.. Immunobiology 220(5):597-604 PMID: 25543283
- 6. Heijink IH et al.. 2003. Sensitivity of IL-5 production to the cAMP-dependent pathway in human T cells is reduced by exogenous IL-2 in a phosphoinositide 3-kinase-dependent way.. Eur J Immunol 33(8):2206-15 PMID: 12884295
- 7. Schaafsma MR et al.. 1991. In vivo production of interleukin-5, granulocyte-macrophage colony-stimulating factor, macrophages colony-stimulating factor, and interleukin-6 during intravenous administration of high-dose interleukin-2 in cancer patients.. Blood 78(8):1981-7 PMID: 1912580
- 8. Chen F et al.. 2022. Anti-allergic function of the cell wall (DeinoWall) from Deinococcus radiodurans.. Mol Immunol 151:103-113 PMID: 36113363
